Onconetix (ONCO) Minority Interest (2023 - 2024)

Onconetix (ONCO) posted quarterly Minority Interest of $7.1 million for Q3 2024, little changed quarter-over-quarter from $7.1 million in Q2 2024.

Onconetix (ONCO) Minority Interest (2023 - 2024) Analysis & Trends

Onconetix (ONCO) has reported Minority Interest for 2 consecutive years, with $7.1 million the latest figure, recorded in Q3 2024.

In Q3 2024, Minority Interest changed N/A year-over-year to $7.1 million; the TTM figure through Sep 2024 stood at $7.1 million (changed N/A YoY), while the FY2023 annual figure was $7.0 million, changed N/A from the prior year.
Minority Interest held at $7.1 million in Q3 2024 per ONCO's latest filing, from $7.1 million in the prior quarter.
Across five years, Minority Interest topped out at $7.1 million in Q3 2024 and bottomed at $7.0 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Onconetix	1.44 Mn	-4.50 Mn	4,303.00

Download Data